RNA-Targeted Therapies and Amyotrophic Lateral Sclerosis
AbstractAmyotrophic lateral sclerosis (ALS) is a fatal motor disease in adults. Its pathophysiology remains mysterious, but tremendous advances have been made with the discovery of the most frequent mutations of its more common familial form linked to the C9ORF72 gene. Although most cases are still considered sporadic, these genetic mutations have revealed the role of RNA production, processing and transport in ALS, and may be important players in all ALS forms. There are no disease-modifying treatments for adult human neurodegenerative diseases, including ALS. As in spinal muscular atrophy, RNA-targeted therapies have been proposed as potential strategies for treating this neurodegenerative disorder. Successes achieved in various animal models of ALS have proven that RNA therapies are both safe and effective. With careful consideration of the applicability of such therapies in humans, it is possible to anticipate ongoing in vivo research and clinical trial development of RNA therapies for treating ALS. View Full-Text
Share & Cite This Article
Mathis, S.; Le Masson, G. RNA-Targeted Therapies and Amyotrophic Lateral Sclerosis. Biomedicines 2018, 6, 9.
Mathis S, Le Masson G. RNA-Targeted Therapies and Amyotrophic Lateral Sclerosis. Biomedicines. 2018; 6(1):9.Chicago/Turabian Style
Mathis, Stéphane; Le Masson, Gwendal. 2018. "RNA-Targeted Therapies and Amyotrophic Lateral Sclerosis." Biomedicines 6, no. 1: 9.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.